Join Now

Utah Life Sciences News & Events

American Society of Nephrology and Renalytix Co-Host Virtual Capital Markets Day for Kidney Health

February 12, 2021

RenalytixAI co-hosted a Capital Markets Day for Kidney Health with the American Society of Nephrology yesterday, Feb. 11. The virtual event brought together a broad group of delegates representing the kidney community, including leading clinicians, representatives of U.S. government health agencies, kidney care innovators and investors focused on life sciences and medical technology, for a series of presentations and panel discussions on the challenges and innovations arising from kidney health and the market opportunity in this area.

“Partnering with the American Society of Nephrology to support events such as the Capital Markets Day for Kidney Health demonstrates the passion and commitment of RenalytixAI to advancing the diagnosis and treatment of chronic kidney disease,” said Kelvyn Cullimore, president and CEO of BioUtah.

Kidney diseases affects 850 million individuals worldwide, including over 37 million Americans, costing the U.S. healthcare system over $120 billion per year in Medicare spending alone.

The Capital Markets Day for Kidney Health event featured keynote addresses by Susan E. Quaggin, MD, FRCP(C), FASN, President, American Society of Nephrology and Chief, Division of Nephrology and Hypertension, Director, Feingberg Cardiovascular and Renal Research Institute, Charles Horace Mayo Professor of Medicine at Northwestern University; and Steven Coca, DO, MS, Associate Professor of Medicine Icahn School of Medicine at Mount Sinai, New York and co-founder of RenalytixAI. RenalytixAI CEO James McCullough also participated in a panel discussion on lead IPOs in kidney disease in 2020.

“Kidney disease is one of the biggest unmet public health needs today. New advancements in precision medicine coupled with significant recent changes in reimbursement and regulatory policies have made kidney disease one of the most attractive areas for innovation and investment in the healthcare space,” said James McCullough, CEO of RenalytixAI.

Despite the significant patient need, awareness and new product development has lagged behind many other fields, until now. There is a trend among healthcare companies, medical providers, organizations, and researchers to assess early-stage prognosis and end-to-end integrated solutions for kidney disease in an effort to prevent the economic and health impacts.

“Better management in kidney disease is happening now, and the roster of speakers today are innovators in their field and at the cutting edge of transforming the way we understand the progression of early-to-end-stage kidney disease,” said Susan E. Quaggin, MD. “As we begin to change the consequences of kidney disease for patients through the use of emerging technologies, we expect to begin to see better outcomes for patients as well as benefits in the health system.”

The list of speakers participating in the Capital Markets Day for Kidney Health included:

  • Amy P. Abernathy, MD, PhD, US Food and Drug Administration
  • Daniel Arias, Stifel Financial Corp.
  • Randy Baron, Pinnacle Associates
  • Sara Barrington, Verici DX Limited
  • Steven G. Coca, DO, MS, Icahn School of Medicine at Mount Sinai, Co-Founder, RenalytixAI
  • Jennifer Erickson, Former White House Office of Science and Technology Policy, Obama Administration
  • Tod Ibrahim, American Society of Nephrology
  • Alan S. Kliger, MD, Yale University School of Medicine
  • Leslie Trigg, Outset Medical, Inc.
  • Kevin Longino, National Kidney Foundation
  • Rachel N. Meyer, American Society of Nephrology
  • James McCullough, RenalytixAI
  • Susan E. Quaggin, MD, FASN, American Society of Nephrology, Northwestern University
  • Anne Rohall-Andrade, Living Kidney Donor, Former HHS Office of Assistant Secretary for Health, Trump Administration
  • Prabir Roy-Chaudhury, MD, PhD, FRCP, University of North Carolina, Chapel Hill, American Society of Nephrology
  • Jeffrey Shuren, MD, JD, US Food and Drug Administration
  • Boris Vuchic, Crescent Rock Capital